BioCentury
ARTICLE | Company News

Nuvelo licenses anticoagulant from Dendreon

February 5, 2004 8:00 AM UTC

NUVO received a worldwide license to DNDN's recombinant nematode anticoagulant protein c2 (rNAPc2) and all other rNAPc proteins. DNDN will receive a $4 million upfront payment in cash and stock and is eligible for milestones and royalties. DNDN, which said the deal will let it focus on oncology, gained the compounds through its 2003 acquisition of Corvas. ...